Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Abnormal blood and lymphatic vessels create a hostile tumor microenvironment
characterized by hypoxia, low pH, and elevated interstitial fluid pressure. These …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Angiogenesis—the process of new blood-vessel growth—has an essential role in
development, reproduction and repair. However, pathological angiogenesis occurs not only …

Thrombospondins TSP-1 and TSP-2 are potent endogenous inhibitors of angiogenesis.
They inhibit angiogenesis through direct effects on endothelial cell migration, proliferation …

Angiogenesis inhibitors for the treatment of cancer have now been approved by the Food
and Drug Administration in the United States, and in 28 other countries including China …

In addition to proliferating cancer cells and various types of normal cells, such as those of
the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Vascular endothelial growth factor (VEGF) was originally identified as an endothelial cell
specific growth factor stimulating angiogenesis and vascular permeability. Some family …

Pathological angiogenesis—driven by an imbalance of pro-and antiangiogenic signaling—
is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in …